Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma

Glucagon-like Peptide-1 Metabolism and Acute Neprilysin Inhibition

NCT03508739 ·Status: SUSPENDED ·Phase: PHASE3

Double Blind Placebo Study of JARDIANCE® (Empagliflozin) in Prehypertensives Type II Diabetics

NCT01001962 ·Status: UNKNOWN ·Phase: PHASE4

SGLT2 Inhibition and Left Ventricular Mass

NCT02728453 ·Status: TERMINATED ·Phase: PHASE4

Empagliflozin as a Treatment for Severe Congenital Neutropenia Due to G6PC3 Deficiency

NCT05078879 ·Status: COMPLETED ·Phase: PHASE1

Study of Safety and Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes And Hypertension (MK-8835-042)

NCT01096667 ·Status: COMPLETED ·Phase: PHASE2

How Does the Diabetes Drug, Pioglitazone, Reduce Protein Loss in the Urine?

NCT00749047 ·Status: UNKNOWN ·Phase: PHASE4

A Study To Evaluate The Safety And Tolerability Of PF-03882845 In Patients With Type 2 Diabetic Nephropathy

NCT01488877 ·Status: TERMINATED ·Phase: PHASE1

Efficacy and Safety of Empagliflozin (BI 10773) in Patients With Type 2 Diabetes and Renal Impairment

NCT01164501 ·Status: COMPLETED ·Phase: PHASE3

The Effect of Sodium-Glucose Cotransporter 2 Inhibitors on Advanced Glycation End Products

NCT02768220 ·Status: WITHDRAWN ·Phase: PHASE4

Pancreas Allotransplantation for Diabetic Nephropathy and Mild Chronic REnal fAilure Stage Study

NCT01067950 ·Status: UNKNOWN ·Phase: PHASE3

Effects of Dapagliflozin on Kidney Function (Glomerular Filtration Rate) in Subjects With Type 2 Diabetes

NCT00976495 ·Status: COMPLETED ·Phase: PHASE2

Safety and Efficacy of Empagliflozin in GSD1b Patients With Neutropenia

NCT04930627 ·Status: UNKNOWN ·Phase: PHASE2

A Study to Investigate the Mechanistic Effects of Dapagliflozin Alone or in Combination With Balcinrenone, Compared to Balcinrenone and Placebo on Body Fluid and Electrolyte Handling and Energy Metabolism in Participants Over 50 Years of Age With Chronic Kidney Disease.

NCT05884866 ·Status: COMPLETED ·Phase: PHASE2

24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and Hypertension

NCT02182830 ·Status: COMPLETED ·Phase: PHASE3

Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease (EMPA-PKD)

NCT06391450 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4

Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin (JNJ-28431754) in Otherwise Healthy Obese Volunteers

NCT01756404 ·Status: COMPLETED ·Phase: PHASE1

A Study of the Effects of Canagliflozin on Plasma Volume in Patients With Type 2 Diabetes Mellitus

NCT01483781 ·Status: COMPLETED ·Phase: PHASE1

Efficacy Of Sodium Glucose Transporter Inhibitor (SGLT2I) In Adult Patients With Congenital Heart Disease

NCT06260059 ·Status: RECRUITING ·Phase: PHASE4

Safety, Tolerability, and Pharmacokinetics of UX053 in Patients With Glycogen Storage Disease Type III (GSD III)

NCT04990388 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease

NCT03492580 ·Status: COMPLETED

Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Kidney Function in Advanced Chronic Kidney Disease

NCT06982079 ·Status: RECRUITING ·Phase: PHASE3

SGLT2 Inhibitors As First Line Therapy to Prevent Renal Decline in Type 2 Diabetes

NCT05345327 ·Status: RECRUITING ·Phase: PHASE3

Evaluation of Empagliflozin vs Standard Care in Veterans With Prediabetes

NCT06828731 ·Status: COMPLETED ·Phase: PHASE1

Treating the Metabolic Syndrome With a Sodium-glucose Cotransporter-2 Inhibitor

NCT07065357 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE3

Effects Of Sodium Glucose Cotranspoter 2 Inhibitors On Heart And Kidneys In Fabry Disease Patients

NCT05710367 ·Status: UNKNOWN ·Phase: PHASE2